Visalytics
Visalytics
approved EB-2 (NIW)

Associate Scientist

Biomedical Science · India · 2025-06-12

Processing Time
525 days
Decision Date
2025-06-12
Location
Pennsylvania
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to continue his research in biomedical science, specifically investigating anticancer therapeutics through high-throughput screening of novel small molecules like benzothiazoles and imidazothiazole-chalcones. His work focuses on identifying compounds with selective cytotoxicity and strong DNA-binding properties to develop personalized cancer treatment strategies. The endeavor aims to discover compounds that arrest tumor progression while minimizing side effects for various human tumor cell lines.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses cancer, a leading public health challenge, and contributes to U.S. medical innovation in oncology.

2 Well-positioned to Advance the Endeavor Met

The petitioner has an extensive publication record, high citation counts, and has received institutional and government funding for his research.

3 Balance of Interests Met

The petitioner's ability to discover compounds that arrest tumor progression makes his continued work in the U.S. highly beneficial, justifying a waiver of the labor certification.

Why This Petition Was Approved

The petition was approved based on the petitioner's 19 peer-reviewed publications and over 578 citations, with several articles ranking in the top 10% of their field. He demonstrated significant influence through 45 peer-reviewed manuscript evaluations and editorial board service for eScience Research and Cancers. The case successfully satisfied all three Dhanasar prongs by highlighting the national importance of oncology research and the petitioner's proven track record in identifying potent anticancer compounds.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Independent
Grants
Judging Experience
Original Contributions

Similar Cases

Research Scientist

Biotechnology · Iran

WeGreened EB-2 (NIW) approved
Maryland 470 days 2025-02-28
The petitioner proposes to continue research in molecular biology focusing on the roles of specific proteins and signaling pathways in cancer development. The work involves studying compounds that disrupt survival signals in cancer cells to design highly effective, targeted therapies. The goal is to improve patient survival rates and enhance the precision of cancer treatments globally.
View Case

Postdoctoral Researcher

Pharmaceuticals · Bangladesh

WeGreened EB-2 (NIW) approved
Illinois 535 days 2026-01-16
The petitioner proposes to continue research in clinical pharmaceutical sciences, specifically focusing on understanding cancer development at the molecular level. The work involves investigating mechanisms such as genome instability and replication stress to identify actionable molecular targets for cost-conscious therapeutic strategies.
View Case

Research Fellow

Biotechnology · Russia

WeGreened EB-2 (NIW) approved
Massachusetts 287 days 2025-02-10
The petitioner proposes to continue research in biomedical science with a focus on disease modeling, targeted therapy development, and the molecular characterization of rare tumors. The work involves genomic analysis of pediatric and adult tumors to enable personalized treatments and validate the effectiveness of drugs like seribantumab and zenocutuzumab. The intended impact is to address urgent gaps in oncology and overcome drug resistance mechanisms in under-researched cancers.
View Case

Postdoctoral Researcher

Biotechnology · Taiwan

WeGreened EB-2 (NIW) approved
Maryland 26 days 2025-06-02
The petitioner proposes to continue research in cancer biology, specifically exploring the molecular mechanisms behind tumor progression and drug resistance. This work focuses on identifying novel therapeutic targets to inform the development of advanced combination therapies and precision medicine paradigms. The intended impact is to improve patient survival rates by creating safer and more effective treatment options for cancers that have evolved resistance to conventional therapies.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Biotechnology cases More cases from India

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-06-12.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 525 days
Criteria Met 3 / 3
Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,895
Success Rate 54.2%
Sustained 2,112
Dismissed 1,687

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in India All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist